SAN DIEGO--(BUSINESS WIRE)--PURE Bioscience (NASDAQ:PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today reported product revenues for the fiscal third quarter ended April 30, 2010 of $563,500, up from product revenues of $129,900 in the same quarter of the prior fiscal year. The Company reported a net loss of $1,610,000 or $(0.05) per share for the fiscal third quarter, compared with a net loss of $1,545,600 or $(0.05) per share in the third fiscal quarter last year.
